老百姓2025年年度报告（英文版）

LBX Pharmacy Chain Joint Stock Company2025 Annual Report 1 / 384 Stock Code: 603883 Company Abbreviation: LBX LBX Pharmacy Chain Joint Stock Company 2025 Annual Report (In case of any discrepancy between the Chinese and English versions of this document, the Chinese version shall prevail.)LBX Pharmacy Chain Joint Stock Company2025 Annual Report 2 / 384 Important Notes I. The Board of Directors, the directors and officers of the Company warrant that the contents of this Annual Report are true, accurate and complete, free from false records, misleading statements or major omissions, and that they will bear several and joint liability. II. All directors of the Company attended the Board of Directors meetings. III. Ernst & Young Hua Ming LLP issued a standard unqualified auditor's report for the Company. IV. Xie Zilong, the Company's principal, Chen Lishan, person in charge of accounting work, and Shi Lei, the person in charge of accounting department (chief accountant) declare as follows: We warrant the truthfulness, accuracy, and completeness of the financial report in this Annual Report. V. Profit distribution plan or plan for capitalization of capital reserves for the reporting period approved by the resolution of the Board of Directors As approved at the 14th meeting of the fifth Board of Directors upon deliberation on April 22, 2026, the Company intends to distribute cash dividends of RMB 0.27 (tax-inclusive) for every 10 shares to all shareholders based on the total share capital on the record date for equity distribution. The Company will not issue bonus shares or convert capital reserve into its share capital. As of March 31, 2026, the total share capital of the Company is 758,890,236 shares, and the Company intends to distribute cash dividends of RMB 204,900,364 (tax-inclusive). The total amount of cash dividends proposed by the Company in 2025 (including tax) was RMB 311,144,997(including interim dividends of RMB 106,244,633 in 2025), accounting for 81.48% of the net profit attributable to the parent company in 2025. The profit distribution proposal was submitted to the 2025 annual shareholders' meeting of the Company for deliberation. Information on the Parent Company's Unrecovered Losses and Their Impacts on the Company's Dividend Distribution and Other Matters as of the End of the Reporting Period □Applicable "√Not Applicable" VI. Risk statement regarding forward-looking statements √Applicable □Not Applicable The forward-looking statements involved in this Report, including future plans and development strategies, do not constitute substantial commitments by the Company to investors. Please pay attention to investment risks. VII. Whether there is any non-operational occupation of funds by the controlling shareholder and other related parties No LBX Pharmacy Chain Joint Stock Company2025 Annual Report 3 / 384 VIII. Whether there was any external guarantee in violation of the establis